Diaceutics PLC
DXRX.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £32,158 | £23,699 | £19,504 | £13,943 |
| % Growth | 35.7% | 21.5% | 39.9% | – |
| Cost of Goods Sold | £3,888 | £3,993 | £5,467 | £3,377 |
| Gross Profit | £28,270 | £19,706 | £14,037 | £10,566 |
| % Margin | 87.9% | 83.2% | 72% | 75.8% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £30,742 | £22,784 | £16,280 | £11,877 |
| SG&A Expenses | £30,742 | £22,784 | £13,706 | £10,253 |
| Sales & Mktg Exp. | £0 | £0 | -£2,574 | -£1,624 |
| Other Operating Expenses | -£17 | -£60 | £0 | £0 |
| Operating Expenses | £30,725 | £22,724 | £13,706 | £10,253 |
| Operating Income | -£2,455 | -£3,018 | £575 | £550 |
| % Margin | -7.6% | -12.7% | 2.9% | 3.9% |
| Other Income/Exp. Net | £547 | £580 | -£11 | -£88 |
| Pre-Tax Income | -£1,908 | -£2,438 | £564 | £462 |
| Tax Expense | -£205 | -£692 | -£160 | -£99 |
| Net Income | -£1,703 | -£1,746 | £724 | £561 |
| % Margin | -5.3% | -7.4% | 3.7% | 4% |
| EPS | -0.02 | -0.021 | 0.009 | 0.007 |
| % Growth | 2.4% | -340.7% | 28.4% | – |
| EPS Diluted | -0.02 | -0.021 | 0.008 | 0.007 |
| Weighted Avg Shares Out | 84,454 | 84,227 | 84,150 | 83,936 |
| Weighted Avg Shares Out Dil | 84,454 | 84,227 | 86,090 | 84,942 |
| Supplemental Information | – | – | – | – |
| Interest Income | £601 | £646 | £111 | £0 |
| Interest Expense | £54 | £66 | £122 | £88 |
| Depreciation & Amortization | £4,627 | £4,773 | £3,008 | £1,799 |
| EBITDA | £2,773 | £2,359 | £3,608 | £2,349 |
| % Margin | 8.6% | 10% | 18.5% | 16.8% |